Article
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
Cancer - 1 Dec 2013
Ma Brigette B Y, Chan Stephen L, Ho Wing M, Lau Wilson, Mo Frankie, Hui Edwin P, Chan Charles, Poon Annette, Dattatray Rasalkar D, Wong S C Cesar, To Ka F, King Ann D, Ahuja Anil, Chan Anthony T C
Abstract excerpt
BACKGROUND: This study evaluated the activity of 2 schedules of erlotinib in combination with chemotherapy, and the prognostic significance of serum amphiregulin (AREG) and transforming growth factor alpha (TGFa) in metastatic colorectal cancer. METHODS: A total of 60 untreated patients were randomized to a "continuous" (CON; erlotinib 100 mg daily) or an "intermittent" (INT; erlotinib 150 mg on alternate day on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.